News
Media
Conferences
CME/CE
Partners
Publications
Resources
Subscribe

Opinion|Videos|December 9, 2024

NMOSD Management with New FDA-approved Agents to Reduce Relapse and Hospitalization Rates

Author(s)Michael Levy, MD, PhD

Key Takeaways

Early and aggressive treatment strategies are crucial in reducing NMOSD relapse and hospitalization rates.
Personalized treatment plans should incorporate new therapeutic agents and monitoring protocols for optimal outcomes.
Collaboration with multidisciplinary teams and patient education are essential in effective NMOSD management.
Sharing insights and experiences with peers enhances understanding and implementation of management strategies.

SHOW MORE

A panelist discusses how neurologists can adapt their NMOSD management strategies based on recent findings about relapse and hospitalization rates, sharing practical advice and clinical experience for optimizing patient outcomes.

Episodes in this series

Michael Levy, MD, PhD, is featured in this series.

EP. 1 Current Treatment Landscape of AQP4-IgG+ NMOSD and Considerations on Relapse Rates

Michael Levy, MD, PhD, is featured in this series.

EP. 2 Shared Decision-making for Selection of FDA-approved Therapies for NMOSD

Michael Levy, MD, PhD, is featured in this series.

EP. 3 Implications of Relapse and Hospitalization Rates with Rituximab Use in NMOSD Management

Michael Levy, MD, PhD, is featured in this series.

EP. 4 NMOSD Management with New FDA-approved Agents to Reduce Relapse and Hospitalization Rates

Video content above is prompted by the following:

In your clinical practice, how have you adapted your approach to NMOSD management in light of these recent findings on relapse and hospitalization rates?
What advice do you have for other neurologists in managing patients with NMOSD and reducing relapse/hospitalization rates?

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related Content

Efgartigimod Meets Primary Endpoint in Phase 3 ALKIVIA Trial of Autoimmune Myositis

August 17th 2026

Why Insurance Coverage Has Become a Multidisciplinary Care Problem in Spinal Muscular Atrophy

ByMariane Hernandez,Isabella Ciccone, MPH,W. Bryan Burnette, MD

August 17th 2026

This Week on NeurologyLive® — August 17, 2026

ByIsabella Ciccone, MPH

August 17th 2026

Zoster Vaccine Shows Strong Effectiveness in Patients With Multiple Sclerosis

August 16th 2026

NeurologyLive® Brain Games: August 16, 2026

ByLouie Pasculli,Marco Meglio

Published: August 16th 2026 | Updated: August 13th 2026

Latest CME

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

James F. Howard Jr, MD, FAAN

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Zarazuela Zolkipli-Cunningham, MBChB, MRCP; Mary Kay Koenig, MD; Perry Shieh, MD, PhD, FAAN, FANA

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Basil T. Darras, MD

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Karissa Gable, MD

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Anne M. Connolly, MD, FAAN; Amy Moore, PhD

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Jessica Oswald, MD, MPH; Jeremy A. Adler, DMSc, PA-C; Amanda Nasser, MS, NP

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA, FASCO; Girish Dhall, MD

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

Millie Das, MD; Wade Iams, MD, MSCI; Ruham Nasany, MD

Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis

Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

FDA Approves Tau PET Tracer MK-6240 for Alzheimer Diagnostic Workup

FDA Clears Phase 2 Trial for Demyelinating Agent Lucid-MS in Progressive Multiple Sclerosis

Zoster Vaccine Shows Strong Effectiveness in Patients With Multiple Sclerosis

Voyager to Advance 2 Tau-Targeted Alzheimer Therapies Toward Key Clinical Milestones

Efgartigimod Meets Primary Endpoint in Phase 3 ALKIVIA Trial of Autoimmune Myositis